Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Hill, Kristen S ^a   Gaziova, Ivana ^a   Harrigal, Lindsay ^a   Guerra, Yvette A ^a   Qiu, Suimin ^a,b   Sastry, Sarita K ^a,b   Arumugam, Thiruvengadam ^c   Logsdon, Craig D ^c   Elferink, Lisa A ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; INTERLEUKIN 8; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; BLOOD VESSELS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-8; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84864007949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040420     Document Type: Article

References (49)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M, (2011) Pancreatic cancer. Lancet 378: 607-620.
3. Stathis A, Moore MJ, (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172.
4. Wong HH, Lemoine NR, (2009) Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422.
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
6. Delpu Y, Hanoun N, Lulka H, Sicard F, Selves J, et al. (2011) Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics 12: 15-24.
7. Hruban RH, Goggins M, Parsons J, Kern SE, (2000) Progression model for pancreatic cancer. Clin Cancer Res 6: 2969-2972.
8. Shi C, Hong SM, Lim P, Kamiyama H, Khan M, et al. (2009) KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res 7: 230-236.
9. de La OJ, Emerson LL, Goodman JL, Froebe SC, Illum BE, et al. (2008) Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A 105: 18907-18912.
10. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126.
11. Goggins M, Hruban RH, Kern SE, (2000) BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 156: 1767-1771.
12. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, et al. (2000) Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60: 2002-2006.
13. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR, (1995) Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55: 1129-1138.
14. Kopantzev EP, Melekhina OV, Kopantseva MR, Mochal'nikova VV, Vinogradova TV, et al. (2009) Secreted growth factors from stromal fibroblasts of the human lung and pancreatic carcinomas. Dokl Biol Sci 429: 583-586.
15. Xu D, Matsuo Y, Ma J, Koide S, Ochi N, et al. (2010) Cancer cell-derived IL-1alpha promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells. J Surg Oncol 102: 469-477.
16. Nakamura T, Sakai K, Matsumoto K, (2011) Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 26: 188-202.
17. Trusolino L, Bertotti A, Comoglio PM, (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848.
18. Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, et al. (2006) Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol 12: 3878-3882.
19. Zhu GH, Huang C, Qiu ZJ, Liu J, Zhang ZH, et al. (2011) Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci 56: 1090-1098.
20. La Rosa S, Uccella S, Capella C, Erba S, Sessa F, (2000) Localization of Hepatocyte Growth Factor and Its Receptor met in Endocrine Cells and Related Tumors of the Gut and Pancreas: An Immunohistochemical Study. Endocr Pathol 11: 315-329.
21. Furukawa T, Duguid WP, Kobari M, Matsuno S, Tsao MS, (1995) Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 147: 889-895.
22. Ebert M, Yokoyama M, Friess H, Buchler MW, Korc M, (1994) Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 54: 5775-5778.
23. Hill KS, Lorinczi M, Elferink LA, (2010) Altered Down Regulation of the Receptor Tyrosine KInase Met in Pancreatic Adenocarcinoma Cells. J Exp Ther Oncol 8: 297-312.
24. Zhang YW, Staal B, Essenburg C, Su Y, Kang L, et al. (2010) MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 70: 6880-6890.
25. Qazi BS, Tang K, Qazi A, (2011) Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam 2011: 908468.
26. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435.
27. Jin H, Yang R, Zheng Z, Romero M, Ross J, et al. (2008) MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 68: 4360-4368.
28. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, et al. (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641.
29. Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, et al. (1992) Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ 3: 11-20.
30. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68: 918-926.
31. Yokoi K, Kim SJ, Thaker P, Yazici S, Nam DH, et al. (2005) Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia 7: 696-704.
32. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
33. Zhang YW, Su Y, Volpert OV, Vande Woude GF, (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 100: 12718-12723.
34. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, et al. (2003) A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63: 5462-5469.
35. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, et al. (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67: 4408-4417.
36. Zeng H, Yu H, Lu L, Jain D, Kidd MS, et al. (2011) Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas 40: 657-663.
37. Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, et al. (2007) The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 14: 2600-2607.
38. Neesse A, Michl P, Frese KK, Feig C, Cook N, et al. (2011) Stromal biology and therapy in pancreatic cancer. Gut 60: 861-868.
39. Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, et al. (2011) Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 121: 4106-4117.
40. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, et al. (2001) Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61: 7518-7524.
41. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T, (2004) Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 11: 419-430.
42. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K, (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88: 2239-2245.
43. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, et al. (2010) A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 66: 1051-1057.
44. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, et al. (1999) Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5: 3711-3721.
45. Matsuo Y, Sawai H, Funahashi H, Takahashi H, Sakamoto M, et al. (2004) Enhanced angiogenesis due to inflammatory cytokines from pancreatic cancer cell lines and relation to metastatic potential. Pancreas 28: 344-352.
46. Singh S, Varney M, Singh RK, (2009) Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 69: 411-415.
47. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N, et al. (2003) Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 22: 765-771.
48. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, et al. (2009) Ras activity levels control the development of pancreatic diseases. Gastroenterology 137: 1072-1082, 1082 e1071-1076.
49. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, et al. (2010) Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 70: 1130-1140.